Progestins in Prostatic Cancer

  • L. Denis
  • C. Bouffioux
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


Progestins are synthetic compounds with progestational activity. One group of these compounds related to 17-alpha-hydroxyprogesterone has mainly progestational effects while another group exerts more anti-androgenic activity. This paper reviews the effect of treatment of the first group of compounds in patients with advanced prostatic cancer.


Prostatic Cancer Advanced Prostatic Cancer Medroxyprogesterone Acetate Cyproterone Acetate Bilateral Orchiectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Gutierrez, New horizons in surgical management of carcinoma of the prostate gland, Amer. J. Surg. 78: 147 (1949).PubMedCrossRefGoogle Scholar
  2. 2.
    J. Trunnel and B. Dubby, Influence of certain steroids on behaviour of human prostatic cancer, Trans. N.Y. Acad. Sci. 12: 238 (1950).CrossRefGoogle Scholar
  3. 3.
    J. Geller, B. Fruchtman, H. Newman, J. Roberts, and R. Silva, Effect of progestational agents on carcinoma of the prostate, Cancer Chemother. Rep. 51: 41 (1967).PubMedGoogle Scholar
  4. 4.
    G. Popelier, Behandlung des Prostatakarcinoms mit Gestagenen, Urologe A 12: 134 (1973).PubMedGoogle Scholar
  5. 5.
    D. Johnson, K. Keasler, and A. Ayala, Megestrol acetate for treatment of advanced carcinoma of the prostate, J. Surg. Oncol. 7: 9 (1975).PubMedCrossRefGoogle Scholar
  6. 6.
    G. Sala, B. Camerino, and C. Cavallero, Progestational activity of 6 alpha-methyl-17-alpha-hydroxyprogesterone acetate, Acta Endocrinol. 29: 508 (1958).PubMedGoogle Scholar
  7. 7.
    Y.C. Babcock, E.S. Gutsell, N.H. Heve, Y.A. Hogg, Y.C. Stucky, W.E. Barnes, and W.E. Dublin, 6 alpha-methyl-17 alpha-hydroxy-progesterone-17-acylates: A new class of potent progestins, J. Am. Chem. Soc. 80: 2904 (1958).CrossRefGoogle Scholar
  8. 8.
    S. Iacobelli and A.D. Marco, “Role of Medroxyprogesterone in Endocrine Related Tumors,” Raven Press, New York (1980), p.29.Google Scholar
  9. 9.
    O. Ferulano, F. Petrarola, and A. Castaldo, Trattamento del cancro della prostata con il controllo dell’arco dienfalo-ipofisario, Minerva Urologica 24: 274 (1972).PubMedGoogle Scholar
  10. 10.
    A. Kondo and Y. Saito, Gestagen Therapy of Benign Prostatic Hyperplasia and Prostatic Carcinoma, Jap. J. Urol. 36: 730 (1974).Google Scholar
  11. 11.
    D.P. Byar, VACURG Studies on Prostatic Cancer and its Treatment, in: “Urologic Pathology: The Prostate,” M. Tannenbaum, ed., Lea & Febiger, Philadelphia (1977), p. 241.Google Scholar
  12. 12.
    S. Rafla and R. Johnson, The treatment of advanced prostatic carcinoma with medroxyprogesterone, Current Therapy Research, 16: 261 (1974).Google Scholar
  13. 13.
    C. Bouffioux, Le Cancer de la Prostate, Acta Urol. Belg, 47: 189 (1979).PubMedGoogle Scholar
  14. 14.
    G. Prout Jr. and L. Denis, Unpublished Data on Pilot Trial, Prostate StudyGroup, 1962 Grant GYP 5631.Google Scholar
  15. 15.
    L. Denis and G. Declercq, Progestagens in Prostatic Cancer, Eur. Urol. 4: 162 (1978).PubMedGoogle Scholar
  16. 16.
    C. Bouffioux, Treatment of Prostatic Cancer with Medroxyprogesterone Acetate (MAP), in: “Bladder Tumors and Other Topics in Urological Oncology,” M. Pavone-Macaluso, P.H. Smith, and F. Edsmyr, eds., Plenum Press, London and New York (1980), p.463.CrossRefGoogle Scholar
  17. 17.
    A. Rifkind, H. Kulin, C. Cargille, P. Rayford, and G. Ross, Suppression of urinary excretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH) by medroxyprogesterone acetate, J. Clin. Endocr. 29: 506 (1969).PubMedCrossRefGoogle Scholar
  18. 18.
    C.W. Bardin and J.F. Catterall, Testosterone: A Major Determinant of extragenital Sexual Dimorphism, Science 211: 1285 (1981).PubMedCrossRefGoogle Scholar
  19. 19.
    W.W. Scott, Rationale and results of primary endocrine therapy in patients with prostatic cancer, Cancer, 32: 1119 (1973).PubMedCrossRefGoogle Scholar
  20. 20.
    D.S. Coffey and J.T. Isaacs, Prostate Tumor Biology and Cell Kinetics Theory, Urology Suppl. 17: 40 (1981).Google Scholar
  21. 21.
    J.F. Altwein and G.H. Jacobi, Hormontherapie des Prostatakarzinoms, Der Urologe A: 19: 350 (1980).Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • L. Denis
    • 1
  • C. Bouffioux
    • 2
  1. 1.A.Z. MiddelheimAntwerpBelgium
  2. 2.Hôpital de BavièreUniversity of LiègeBelgium

Personalised recommendations